Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer

This study is a prospective, multicenter, single arm Phase II exploratory study. It is expected to include 24 first-line patients with small cell lung cancer who have progressed after 6 months of treatment with platinum containing regimens, and receive treatment with irinotecan liposomes combined with cisplatin or carboplatin regimens.

Trial Details

NCT ID

NCT06467786

Phase

PHASE4

Sponsor

Tang-Du Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Irinotecan hydrochloride liposome injection

Locations (sample)

Xi'an, Shannxi, China|34.25833,108.92861

Key Eligibility Criteria

The patient fully understands this study, voluntarily participates and signs an informed consent form (ICF).
Age ≥ 18 years old;
Patients with extensive stage small cell lung cancer diagnosed by pathology or histology;
According to RECIST 1.1 standard, patients have at least one measurable target lesion; For lesions that have undergone radiation therapy in the pas…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →